U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H19F3N4O3
Molecular Weight 396.3644
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PF-04991532

SMILES

C1CCC(C1)C[C@@]([H])(C(=Nc2ccc(cn2)C(=O)O)O)n3cc(C(F)(F)F)nc3

InChI

InChIKey=GKMLFBRLRVQVJO-ZDUSSCGKSA-N
InChI=1S/C18H19F3N4O3/c19-18(20,21)14-9-25(10-23-14)13(7-11-3-1-2-4-11)16(26)24-15-6-5-12(8-22-15)17(27)28/h5-6,8-11,13H,1-4,7H2,(H,27,28)(H,22,24,26)/t13-/m0/s1

HIDE SMILES / InChI

Molecular Formula C18H19F3N4O3
Molecular Weight 396.3644
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800032199

Pfizer was developing PF-04991532, a potent and selective hepatoselective glucokinase activator. PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic rats. F-04991532 reduced plasma glucose concentrations independent of changes in insulin concentrations in a dose-dependent manner both acutely and after 28 days of sub-chronic treatment. PF-04991532 may offer glycemic control without inducing hepatic steatosis supporting the evaluation of tissue specific activators in clinical trials. In 2012, Pfizer discontinued the development of the compound.

Originator

Curator's Comment:: # Pfizer

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
90.0 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1436 ng/mL
450 mg single, oral
dose: 450 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PF-04991532 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3669 ng × h/mL
450 mg single, oral
dose: 450 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PF-04991532 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1898 h
450 mg single, oral
dose: 450 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PF-04991532 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
PubMed

PubMed

TitleDatePubMed
The hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic rats.
2014
Comparison of the circulating metabolite profile of PF-04991532, a hepatoselective glucokinase activator, across preclinical species and humans: potential implications in metabolites in safety testing assessment.
2015 Feb
Patents

Sample Use Guides

Tablets 150 mg - 750 mg, all once daily for 84 days
Route of Administration: Oral
PF-04991532 activated human recombinant glucokinase with EC50 90nM
Substance Class Chemical
Created
by admin
on Sat Jun 26 12:41:37 UTC 2021
Edited
by admin
on Sat Jun 26 12:41:37 UTC 2021
Record UNII
AJ212MS2O2
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PF-04991532
Common Name English
3-PYRIDINECARBOXYLIC ACID, 6-(((2S)-3-CYCLOPENTYL-1-OXO-2-(4-(TRIFLUOROMETHYL)-1H-IMIDAZOL-1-YL)PROPYL)AMINO)-
Systematic Name English
Code System Code Type Description
CAS
1215197-37-7
Created by admin on Sat Jun 26 12:41:38 UTC 2021 , Edited by admin on Sat Jun 26 12:41:38 UTC 2021
PRIMARY
DRUG BANK
DB11765
Created by admin on Sat Jun 26 12:41:38 UTC 2021 , Edited by admin on Sat Jun 26 12:41:38 UTC 2021
PRIMARY
PUBCHEM
46181428
Created by admin on Sat Jun 26 12:41:38 UTC 2021 , Edited by admin on Sat Jun 26 12:41:38 UTC 2021
PRIMARY
FDA UNII
AJ212MS2O2
Created by admin on Sat Jun 26 12:41:38 UTC 2021 , Edited by admin on Sat Jun 26 12:41:38 UTC 2021
PRIMARY
Related Record Type Details
TRANSPORTER -> SUBSTRATE
a liver-to pancreas ratio of 75-fold for rat and 58-fold for dog presumably due to transporters
TRANSPORTER -> SUBSTRATE
TARGET -> ACTIVATOR
ACTIVATOR
EC50
TRANSPORTER -> SUBSTRATE
Related Record Type Details
ACTIVE MOIETY